Skip to main content


Medical and radiation oncology

Section edited by Dirk Vordermark

This section focuses on clinical research that impacts on the treatment of cancer using systemic chemotherapy, targeted therapy, and radiation.

Page 16 of 16

  1. Content type: Research article

    The Neutrophil to lymphocyte ratio (NLR) has prognostic value in patients with a variety of cancers. However, its prognostic significance in oral squamous cell carcinoma (OSCC) patients has not been fully expl...

    Authors: Hikaru Nakashima, Yuichiro Matsuoka, Ryoji Yoshida, Masashi Nagata, Akiyuki Hirosue, Kenta Kawahara, Junki Sakata, Hidetaka Arita, Akimitsu Hiraki and Hideki Nakayama

    Citation: BMC Cancer 2016 16:41

    Published on:

  2. Content type: Case report

    Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection...

    Authors: Tatiana C. Schneider, Ellen Kapiteijn, Tom van Wezel, Jan W. A. Smit, Jacobus J. M. van der Hoeven and Hans Morreau

    Citation: BMC Cancer 2016 16:31

    Published on:

  3. Content type: Research article

    Trabectedin is an antineoplastic agent used for patients with soft tissue sarcoma (STS) who fail standard-of-care treatment. Real-world data of its performance is scarce. This study evaluates the safety and ef...

    Authors: Fernando A. Angarita, Amanda J. Cannell, Albiruni R. Abdul Razak, Brendan C. Dickson and Martin E. Blackstein

    Citation: BMC Cancer 2016 16:30

    Published on:

  4. Content type: Research article

    Several small studies indicated that the genotype of KIT or platelet-derived growth factor receptor-α (PDGFRA) contributes in part to the level of clinical effectiveness of sunitinib in gastrointestinal stromal t...

    Authors: Peter Reichardt, George D. Demetri, Hans Gelderblom, Piotr Rutkowski, Seock-Ah Im, Sudeep Gupta, Yoon-Koo Kang, Patrick Schöffski, Jochen Schuette, Denis Soulières, Jean-Yves Blay, David Goldstein, Kolette Fly, Xin Huang, Massimo Corsaro, Maria Jose Lechuga…

    Citation: BMC Cancer 2016 16:22

    Published on:

  5. Content type: Research article

    The current study was conducted to examine the activity of a docetaxel/oxaliplatin (DocOx) combination as second line treatment for advanced pancreatic ductal adenocarcinoma (Trial registration: NCT00690300. R...

    Authors: Thomas J. Ettrich, Lukas Perkhofer, Goetz von Wichert, Thomas M. Gress, Patrick Michl, Holger F. Hebart, Petra Büchner-Steudel, Michael Geissler, Rainer Muche, Bettina Danner, Volker Kächele, Andreas W. Berger, Melanie Güthle and Thomas Seufferlein

    Citation: BMC Cancer 2016 16:21

    Published on:

  6. Content type: Research article

    Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Cetuximab ...

    Authors: Denis Soulières, Jose Luis Aguilar, Eric Chen, Krzysztof Misiukiewicz, Scott Ernst, Hyun Jung Lee, Katherine Bryant, Shuang He, Coleman K. Obasaju, Shao-Chun Chang, Steve Chin and Douglas Adkins

    Citation: BMC Cancer 2016 16:19

    Published on:

  7. Content type: Case report

    Signs and symptoms of a rapidly enlarging breast mass are not only important for all clinicians to recognize and assess, but also are not uncommon occurrences. We describe a similar but unique case that develo...

    Authors: Vivek Verma, Sanjay Muttineni, Rajesh R. Kulkarni, Edibaldo Silva-Lopez, William W. West and Robert B. Thompson

    Citation: BMC Cancer 2015 15:1008

    Published on:

  8. Content type: Case report

    Hypereosinophilia, defined by an absolute eosinophil count of more than 1500/mm3, is rarely observed in patients treated for cancer, and rarely imputable to anti-cancer agents. Drug-induced hypereosinophilia u...

    Authors: Diaddin Hamdan, Christophe Leboeuf, Cathy Pereira, Nathalie Jourdan, Laurence Verneuil, Guilhem Bousquet and Anne Janin

    Citation: BMC Cancer 2015 15:993

    Published on:

  9. Content type: Research article

    Surgery and stereotactic ablative radiotherapy (SABR) are both curative treatment options for patients with a stage I non-small cell lung cancer (NSCLC). Consequently, there is growing interest in studying the...

    Authors: Wendy Hopmans, Olga C. Damman, Suresh Senan, Koen J. Hartemink, Egbert F. Smit and Danielle R. M. Timmermans

    Citation: BMC Cancer 2015 15:959

    Published on:

  10. Content type: Research article

    Several studies have shown, that circulating tumor cells (CTC) have a negative prognostic value in colorectal cancer patients. Aim of this study was to evaluate the role of CTC in specifically rectal cancer pa...

    Authors: Sebastian Hinz, Christian Röder, Jürgen Tepel, Alexander Hendricks, Clemens Schafmayer, Thomas Becker and Holger Kalthoff

    Citation: BMC Cancer 2015 15:953

    Published on:

  11. Content type: Case report

    Current knowledge indicate that epirubicin administration in late pregnancy is almost devoid of any fetal cardiotoxicity. We report a twin pregnancy complicated by breast cancer in which epirubicin administrat...

    Authors: Marialuisa Framarino-dei-Malatesta, Giuseppina Perrone, Antonella Giancotti, Flavia Ventriglia, Martina Derme, Isabella Iannini, Valentina Tibaldi, Paola Galoppi, Paolo Sammartino, Gianluca Cascialli and Roberto Brunelli

    Citation: BMC Cancer 2015 15:951

    Published on:

  12. Content type: Research article

    To compare the efficacy and toxicity of irinotecan-based chemotherapy (IBC) and non-irinotecan-based chemotherapy (NIBC) as first-line treatment for stage IIIB/IV non-small cell lung cancer (NSCLC).

    Authors: Xue-Qin Yang, Chong-Yi Li, Ming-Fang Xu, Hong Zhao and Dong Wang

    Citation: BMC Cancer 2015 15:949

    Published on:

  13. Content type: Case report

    Median overall survival (OS) of patients with melanoma brain metastases (MBM) is usually 6 months or less. There are rare reports of patients with treated MBM who survived for years. These outlier cases repres...

    Authors: Sarah Weiss, Farbod Darvishian, Jyothi Tadepalli, Richard Shapiro, John Golfinos, Anna Pavlick, David Polsky, Tomas Kirchhoff and Iman Osman

    Citation: BMC Cancer 2015 15:926

    Published on:

  14. Content type: Research article

    The objective of this study is to explore the off-label use of targeted therapies (TTs) for patients with osteosarcoma registered within the French Sarcoma Group – Bone Tumor Study Group (GSF-GETO) national re...

    Authors: Mathilde Penel-Page, Isabelle Ray-Coquard, Julie Larcade, Magali Girodet, Laure Bouclier, Muriel Rogasik, Nadège Corradini, Natacha Entz-Werle, Laurence Brugieres, Julien Domont, Cyril Lervat, Sophie Piperno-Neumann, Helène Pacquement, Jacques-Olivier Bay, Jean-Claude Gentet, Antoine Thyss…

    Citation: BMC Cancer 2015 15:854

    Published on:

  15. Content type: Research article

    Durability of androgen-deprivation therapy (ADT) for prostate cancer (PC) is limited. Additional selective estrogen receptor modulators (SERMs) may prolong the durability of ADT, because androgen and estrogen ...

    Authors: Tetsuya Fujimura, Satoru Takahashi, Haruki Kume, Tomohiko Urano, Kenichi Takayama, Yuta Yamada, Motofumi Suzuki, Hiroshi Fukuhara, Tohru Nakagawa, Satoshi Inoue and Yukio Homma

    Citation: BMC Cancer 2015 15:836

    Published on:

  16. Content type: Research article

    Locally recurrent non-small cell lung cancer (NSCLC) poses a great challenge to physicians. This study aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin f...

    Authors: Xiaojuan Yu, Jin Li, Xiaoming Zhong and Jingdong He

    Citation: BMC Cancer 2015 15:656

    Published on: